Compare Citius Pharmaceuticals Inc (CTXR) vs Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) (SMFG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) trades at $24.85 (market cap $156.97B). The key difference: Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) is far larger — about 11525× Citius Pharmaceuticals Inc's market cap, and Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) pays a 2.34% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) for 0 Days on average.
| CTXR | SMFG | |
|---|---|---|
Market Cap | $13.62M | $156.97B |
Volume | 132,438 | 1,237,125 |
Sector | Health | Financials |
52-Week High | $1.82 | $27.56 |
52-Week Low | $0.48 | $15.20 |
Typical Hold Time | 16 Days | 0 Days |
Enterprise Value | $3.79M | $12.48T |
Dividend Yield | — | 2.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, but remains in a bearish technical trend with negative profitability metrics. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR sales, though net income margin remains deeply negative at -651.27%. Analyst consensus is strongly bullish with 5 buy ratings and a $5.00 price target, representing significant upside potential from current levels.
While CTXR shows promising commercial progress with its oncology drug launch, the stock faces substantial execution risks due to persistent losses and cash burn. The bullish analyst sentiment contrasts with weak fundamentals, creating a high-risk, high-reward scenario for investors betting on successful commercialization of LYMPHIR in the $400M+ CTCL market.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan)
Sumitomo Mitsui Financial Group is a Japanese financial services company with banking, securities, leasing, and asset management businesses. It serves retail, corporate, and institutional clients.
Read more on SMFG →
